Hepatic Encephalopathy Market Summary

• The Hepatic Encephalopathy market was valued at approximately USD 900 million in 2025 and is expected to grow at a CAGR of 1.2% during the forecast period from 2026 to 2036.
• The Hepatic Encephalopathy Market companies developing therapies include - Bausch Health Companies, Salix Pharmaceuticals, Mallinckrodt Pharmaceuticals, Lupin Limited, Cosmo Pharmaceuticals, ASKA Pharmaceutical, Vedanta Biosciences, Umecrine Cognition, and others.

Hepatic Encephalopathy Market and Epidemiology Analysis

• The current therapeutic market of HE includes one approved drug Xifaxan (Rifaximin) to reduce the risk of recurrence of OHE and for the improvement of hyperammonemia in hepatic encephalopathy, several other therapies. The 7MM treatment market of HE was valued at USD ~800 million in 2022.
• Currently, Xifaxan (rifaximin) is the only approved drug. In 2022, Xifaxan captured a market size of USD ~110 million (revenue from monotherapy use of rifaximin) in the 7MM. 
• Assessments as per DelveInsight’s analysis showed that the majority of cases of HE were found in males as compared to females. In 2022, there were ~1,40,000 males and ~60,000 females affected by HE in the United States.
• In EU4 and the UK, the Germany has the highest number of cases of HE with ~20,000 cases, followed by the UK with ~16,100 cases and France with ~16,000 cases. While Spain consistently occupied the least number of cases i.e. ~11,000 in 2022.
• Based on severity, HE is classified as CHE and OHE. There was a total of ~1,20,000 CHE and ~80,000 OHE cases in 2022 in the United States.
• The United States contributed to the largest diagnosed prevalent cases of Hepatic encephalopathy, accounting for ~60% in 2025.

Factors Affecting the Hepatic Encephalopathy Market Growth

Rising Prevalence of Chronic Liver Diseases

The increasing incidence of liver cirrhosis, alcoholic liver disease, hepatitis infections, and nonalcoholic steatohepatitis (NASH) is significantly contributing to the growing burden of Hepatic Encephalopathy (HE), thereby driving market demand.

Growing Awareness and Early Diagnosis

Improved awareness among healthcare professionals and advancements in diagnostic approaches are enabling earlier identification and management of Hepatic Encephalopathy, supporting higher treatment adoption rates.

Increasing Healthcare Expenditure and Supportive Reimbursement

Rising healthcare spending and favorable reimbursement policies in developed markets are improving patient access to Hepatic Encephalopathy therapies and specialty care services.

Expansion of Research and Clinical Activities

Growing investments in clinical trials and research focused on liver diseases and gut-brain axis therapies are expected to create future growth opportunities in the Hepatic Encephalopathy market.

Improving Healthcare Infrastructure in Emerging Markets

Developing countries are witnessing better healthcare accessibility, increasing liver disease awareness, and improved treatment availability, which are collectively supporting market growth globally.

Request a sample to unlock the CAGR for "Hepatic Encephalopathy Market Forecast"

DelveInsight's ‘Hepatic Encephalopathy – Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology, as well as the Hepatic Encephalopathy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Hepatic Encephalopathy market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, Hepatic Encephalopathy patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in Hepatic Encephalopathy and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Hepatic Encephalopathy Disease Understanding

Hepatic Encephalopathy Overview

Hepatic Encephalopathy is a serious neuropsychiatric complication associated with advanced liver disease and liver dysfunction. It occurs when the liver is unable to effectively remove toxins, particularly ammonia, from the bloodstream, leading to impaired brain function. Symptoms of HE can range from mild cognitive impairment and confusion to severe neurological dysfunction, personality changes, and coma. The condition is commonly associated with liver cirrhosis, chronic liver disease, and hypertension.

Hepatic Encephalopathy Diagnosis

The diagnosis of Hepatic Encephalopathy is primarily based on clinical evaluation, patient history, neurological assessment, and identification of underlying liver disease. Physicians may use blood tests to measure ammonia levels and evaluate liver function, while imaging studies such as CT scans or MRI help exclude other neurological conditions. Neuropsychological tests and electroencephalography (EEG) may also assist in assessing cognitive impairment and confirming minimal or overt HE.

Hepatic Encephalopathy Treatment

Treatment for Hepatic Encephalopathy focuses on reducing toxin accumulation, managing symptoms, and treating underlying liver disease. Lactulose is commonly used to lower ammonia absorption in the intestines, while rifaximin is frequently prescribed to reduce ammonia-producing gut bacteria. Additional management strategies include nutritional support, correction of precipitating factors such as infections or gastrointestinal bleeding, and supportive care in severe cases. In advanced liver failure, liver transplantation may be considered as a definitive treatment option.

Further details are provided in the report.

Hepatic Encephalopathy Epidemiology

Hepatic Encephalopathy epidemiology is closely linked to the rising global burden of chronic liver diseases, particularly cirrhosis and liver failure. The condition commonly affects patients with advanced liver disease and is characterized by recurrent cognitive and neurological impairments. Increasing alcohol-related liver disease, viral hepatitis infections, and nonalcoholic steatohepatitis (NASH) are contributing to the growing prevalence of Hepatic Encephalopathy worldwide. The disease imposes a substantial clinical and economic burden due to frequent hospitalizations, high recurrence rates, and reduced quality of life among affected patients.

Key Findings from Hepatic Encephalopathy Epidemiological Analyses and Forecast

• According to DelveInsight’s estimates, the total number of prevalent cases of HE in the 7MM was nearly 210,000 cases in 2025 and is projected to increase during the forecasted period.
• Hepatic Encephalopathy predominantly affected males, with approximately 144,000 males diagnosed compared to 64,000 females in 2025 in the US.
• In the EU4 and the UK, individuals between the age of 45-54 were the most affected by Hepatic Encephalopathy, with approximately 24,000 cases reported in 2025.

Hepatic Encephalopathy Market Recent Developments and Breakthroughs

• In February 2025, Yaqrit announced that its recently acquired ammonia scavenger, L-ornithine phenylacetate (OPA), is progressing to Phase III for treatment of acute hepatic encephalopathy, a life-threatening complication of decompensated cirrhosis.
• EnteroBiotix Limited announced positive results in May 2025 from its Phase Ib clinical trial evaluating EBX-102, the Company’s next-generation oral full-spectrum microbiome product, in patients with liver cirrhosis and Hepatic Encephalopathy. The data were presented during an oral session at the European Association for the Study of the Liver (EASL) Congress 2025, held in Amsterdam, the Netherlands from 7–10 May 2025.

Hepatic Encephalopathy Drug Analysis 

The Hepatic Encephalopathy drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I/II–II clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Hepatic Encephalopathy treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Hepatic Encephalopathy therapeutics market.

Hepatic Encephalopathy Marketed Drugs

Xifaxan (Rifaximin): BAUSCH Health

Xifaxan® (rifaximin) 550 mg tablets, developed and marketed by Salix Pharmaceuticals (a subsidiary of Valeant Pharmaceuticals whose company name changes to BAUSCH Health), are indicated to reduce the risk of recurrent overt hepatic encephalopathy in adults aged =18 years. Rifaximin is a non-absorbed, broad-spectrum, gastrointestinal-selective antibiotic derived from rifamycin that targets both Gram-positive and Gram-negative, aerobic and anaerobic ammonia-producing bacteria, thereby lowering systemic ammonia levels implicated in hepatic encephalopathy. Unlike systemic antibiotics, rifaximin remains within the gastrointestinal tract without significant absorption and exerts its effect by binding to the ß-subunit of bacterial DNA-dependent RNA polymerase, inhibiting transcription by blocking the translocation step following the formation of the first phosphodiester bond.

Note: Detailed marketed therapies assessment will be provided in the final report.

Hepatic Encephalopathy Emerging Drugs

VE303: Vedanta Biosciences

VE303 is an orally administered, wholly owned defined bacterial consortium composed of eight live commensal strains developed to prevent recurrent Clostridioides difficile infection (rCDI). It is formulated as a standardized oral pharmaceutical product manufactured from pure clonal cell banks to ensure consistent quality. The selected strains function synergistically to reduce recurrence by competing with C. difficile for growth substrates and producing secondary bile acids that suppress its proliferation, as well as short-chain fatty acids that enhance gut barrier integrity and mitigate intestinal inflammation. Currently, the drug is in Phase II stage of its development for the treatment of Hepatic Encephalopathy.

Hepatic Encephalopathy Market Outlook

Hepatic encephalopathy is a diagnosis of exclusion marked by neuropsychiatric abnormalities from liver dysfunction. It arises from liver insufficiency or portosystemic shunting and involves a multifactorial etiology, including hyperammonemia, systemic inflammation, gut dysbiosis, neurotransmitter imbalances, and neurotoxins like manganese. Current management of hepatic encephalopathy (HE) centers on reducing intestinal ammonia production and absorption. Non-absorbable disaccharides such as lactulose and lactitol remain the cornerstone of therapy, used for treating acute episodes as well as for primary and secondary prevention; lactitol demonstrates comparable efficacy to lactulose and may offer improved tolerability in some patients. Antibiotics aimed at colonic decontamination, including neomycin, metronidazole, and vancomycin, further decrease ammonia-producing gut bacteria and may also mitigate inflammation and endotoxemia. Second-line and emerging therapies include polyethylene glycol 3350–electrolyte solution, ammonia scavengers, branched-chain amino acids fecal microbiota transplantation, and L-ornithine L-aspartate. Currently, only one drug is approved for Hepatic Encephalopathy treatment i.e. XIFAXAN (Rifaximin) which is an oral small molecule.

Hepatic Encephalopathy Competitive Landscape

Hepatic Encephalopathy Drugs Uptake

This section focuses on the uptake rate of potential Hepatic Encephalopathy (HE) therapies expected to be launched in the market during 2024–2030. The adoption of emerging therapies will depend on the evolving Hepatic Encephalopathy competitive landscape, clinical efficacy and safety outcomes, pricing strategies, reimbursement availability, and order of market entry. Key Hepatic Encephalopathy companies developing novel therapies through pivotal and confirmatory clinical studies must carefully design trial endpoints and comparator strategies to enhance regulatory success, accelerate approvals, and support rapid market uptake across the 7MM.

Hepatic Encephalopathy Clinical Trial Activities

The Hepatic Encephalopathy pipeline report provides comprehensive insights into ongoing and completed clinical trials across Phase III, Phase II, and early-stage development. The report highlights major Hepatic Encephalopathy companies involved in developing innovative therapeutics targeting ammonia reduction, gut microbiota modulation, neuroinflammation, and liver dysfunction to improve disease management and patient outcomes.

Hepatic Encephalopathy Pipeline Development Activities

The Hepatic Encephalopathy clinical trial analysis report covers detailed information regarding strategic collaborations, mergers and acquisitions, licensing agreements, partnerships, regulatory milestones, and patent activities associated with emerging HE therapies. The report also evaluates pipeline expansion strategies and recent advancements adopted by pharmaceutical and biotechnology companies operating within the Hepatic Encephalopathy treatment landscape.

Latest KOL Views on Hepatic Encephalopathy

To understand the real-world treatment landscape and evolving market trends, insights are gathered from Key Opinion Leaders (KOLs) and industry experts through primary research. These expert opinions help validate secondary research findings and provide a better understanding of current treatment approaches, patient dependence on conventional therapies such as lactulose and rifaximin, therapy-switching patterns, accessibility challenges, and expected uptake of novel Hepatic Encephalopathy therapies.

DelveInsight’s analysts interacted with multiple KOLs and subject matter experts across the 7MM to gain insights into the evolving Hepatic Encephalopathy treatment environment. Their perspectives support the identification of unmet medical needs, emerging therapeutic opportunities, and the future impact of upcoming therapies on overall market dynamics.

Hepatic Encephalopathy Drugs Market Qualitative Analysis

The Hepatic Encephalopathy report performs qualitative and Hepatic Encephalopathy market intelligence analysis using analytical frameworks such as SWOT analysis and Conjoint Analysis. SWOT analysis evaluates strengths, weaknesses, opportunities, and threats associated with disease diagnosis, patient awareness, physician adoption, treatment accessibility, cost-effectiveness, and the overall Hepatic Encephalopathy competitive landscape.

Conjoint Analysis assesses approved and emerging therapies based on important attributes including efficacy, safety profile, route of administration, dosing convenience, treatment adherence, and expected order of market entry. Therapies are scored across these parameters to evaluate their overall clinical and commercial potential.

Additionally, therapy safety and tolerability are assessed based on adverse events, long-term compliance, and patient acceptability observed during clinical trials. The analysis also incorporates probability of success and addressable patient population to determine the overall ranking and weightage of emerging therapies within the Hepatic Encephalopathy market.

Hepatic Encephalopathy Therapeutics Market Access and Reimbursement

The Hepatic Encephalopathy therapeutics market report further provides detailed insights into country-wise market accessibility, reimbursement frameworks, and cost-effectiveness of currently available therapies. The Hepatic Encephalopathy Therapeutics Market report also highlights patient support programs, insurance coverage under public and private healthcare systems, reimbursement challenges, and initiatives aimed at improving patient affordability and access to advanced Hepatic Encephalopathy therapies across the major markets.

Scope of the Hepatic Encephalopathy Therapeutics Market Report

• The Hepatic Encephalopathy Therapeutics Market report covers a segment of key events, an executive summary, a descriptive overview of Hepatic Encephalopathy, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Hepatic Encephalopathy market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Hepatic Encephalopathy Therapeutics Market report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Hepatic Encephalopathy market.

Hepatic Encephalopathy Therapeutics Market Report Insights

• Hepatic Encephalopathy Patient Population Forecast
• Hepatic Encephalopathy Therapeutics Market Size
• Hepatic Encephalopathy Pipeline Analysis
• Hepatic Encephalopathy Market Size and Trends
• Hepatic Encephalopathy Market Opportunity (Current and forecasted)

Hepatic Encephalopathy Therapeutics Market Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• Hepatic Encephalopathy Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Hepatic Encephalopathy Treatment Addressable Market (TAM)
• Hepatic Encephalopathy Competitive Landscape
• Hepatic Encephalopathy Major Companies Insights
• Hepatic Encephalopathy Price Trends and Analogue Assessment
• Hepatic Encephalopathy Therapies Drug Adoption/Uptake
• Hepatic Encephalopathy Therapies Peak Patient Share Analysis

Hepatic Encephalopathy Therapeutics Market Report Assessment

• Hepatic Encephalopathy Current Treatment Practices
• Hepatic Encephalopathy Unmet Needs
• Hepatic Encephalopathy Clinical Development Analysis
• Hepatic Encephalopathy Emerging Drugs Product Profiles
• Hepatic Encephalopathy Market Attractiveness
• Hepatic Encephalopathy Qualitative Analysis (SWOT and conjoint analysis)

FAQs

Hepatic Encephalopathy Therapeutics Market Insights

• What was the Hepatic Encephalopathy market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Hepatic Encephalopathy?
• What impact will patent expiry have on the Hepatic Encephalopathy therapy market?
• What are the disease risks, burdens, and unmet needs of Hepatic Encephalopathy? What will be the growth opportunities across the 7MM concerning the patient population with Hepatic Encephalopathy?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Hepatic Encephalopathy? What are the current guidelines for treating Hepatic Encephalopathy in the US, Europe, and Japan?

Reasons to Buy the Hepatic Encephalopathy Therapeutics Market Forecast Report

• The Hepatic Encephalopathy Therapeutics Market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Hepatic Encephalopathy market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Hepatic Encephalopathy market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming Hepatic Encephalopathy companies in the Hepatic Encephalopathy market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Hepatic Encephalopathy market so that the upcoming Hepatic Encephalopathy companies can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.